Metagenomi Therapeutics (MGX) Amortizatization of Intangibles (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Amortizatization of Intangibles of $360000.0 for Q1 2026, down 64.25% year-over-year from $1.0 million in Q1 2025, and down 23.4% quarter-over-quarter from $470000.0 in Q4 2025.
Metagenomi Therapeutics (MGX) Amortizatization of Intangibles (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Amortizatization of Intangibles for 4 consecutive years, with $360000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 64.25% year-over-year to $360000.0; the TTM figure through Mar 2026 stood at $2.4 million (down 60.49% YoY), while the FY2025 annual figure was $3.0 million, down 51.37% from the prior year.
- Amortizatization of Intangibles declined to $360000.0 in Q1 2026 per MGX's latest filing, from $470000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $2.4 million in Q2 2023 and bottomed at $360000.0 in Q1 2026.
- Historically, Amortizatization of Intangibles has averaged $1.4 million across 4 years, with a median of $1.3 million in 2024.
- Annual changes were most pronounced in 2024 — Amortizatization of Intangibles slipped 16.84% — and 2025, when it sank 64.98%.
- Metagenomi Therapeutics' Amortizatization of Intangibles stood at $1.6 million in 2023, then dropped by 17.16% to $1.3 million in 2024, then tumbled by 64.98% to $470000.0 in 2025, then retreated by 23.4% to $360000.0 in 2026.
- Business Quant data shows MGX's Amortizatization of Intangibles at $360000.0 in Q1 2026, $470000.0 in Q4 2025, and $705000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Metagenomi Therapeutics | 46.51 Mn | 46.51 Mn | - | 195,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 195,000.00 |
| Jun 30, 2026 | 195,000.00 |
| Mar 31, 2026 | 360,000.00 |
| Mar 31, 2026 | 360,000.00 |
| Dec 31, 2025 | 470,000.00 |
| Dec 31, 2025 | 470,000.00 |
| Sep 30, 2025 | 705,000.00 |
| Sep 30, 2025 | 705,000.00 |
| Jun 30, 2025 | 818,000.00 |
| Jun 30, 2025 | 818,000.00 |
| Mar 31, 2025 | 1.01 Mn |
| Mar 31, 2025 | 1.01 Mn |
| Dec 31, 2024 | 1.34 Mn |
| Dec 31, 2024 | 1.34 Mn |
| Sep 30, 2024 | 1.63 Mn |
| Sep 30, 2024 | 1.63 Mn |
| Jun 30, 2024 | 1.98 Mn |
| Jun 30, 2024 | 1.98 Mn |
| Mar 31, 2024 | 1.22 Mn |
| Mar 31, 2024 | 1.22 Mn |